SwedenSweden

Biotage acquires Separtis Holding

28.09.2005


Stockholm - In early-October Biotage has acquired Separtis Holding AG, the Swiss, German and Austrian distributor for many Biotage products, formerly the Argonaut Technologies consumable product range.
Biotage will retain all current Separtis employees, assume the leased facilities in Grenzach-Wyhlen, and own all assets of Separtis, which is based in Grellingen, Switzerland, with operating legal entities within Switzerland and Germany. The turnover of the company in 2004 was Euro1.6 million (SEK14.6m) and all revenues were comprised of Biotage products. It is expected the acquisition should result in an annual revenue increase of Euro0.8 million.
In order to efficiently refinance part of the Euro15-million (SEK140m) debt settling regarding the acquisition of Argonaut's business Biotage's board decided in September to increase the share capital by means of an issue of 10 million new shares corresponding to approximately 12% of Biotage's capital and voting rights. That way the share capital is increased by Euro1.6 million (SEK10m) to Euro8.6 million (SEK80.4m).
The set issue price was Euro1.04 (SEK9.70) per share. Each existing share entitled to 1 subscription right and 10 subscription rights entitled to subscription of 1 new share. After deduction of costs, the new share issue brings the company Euro10.1 million (SEK94m) of new capital.

SwedenSweden

17.11.2011

Exton/Helsingborg – A Swedish specialist for improving glucocorticoid replacement therapy has attracted transatlantic attention. DuoCort Pharma AB, based in Helsingborg, was bought by ViroPharma Incorporated, an US-based...

SwedenSweden

01.10.2011

Uppsala/Basel – Swedish life science initiative Uppsala BIO is set to team up with drugmaker Hoffman-La Roche AG. For the next three years, the cluster will become the ninth member – and the first from Europe – of the Swiss...

SwedenSweden

01.10.2011

Uppsala – Backed by strong clinical research, the development of Orexo AB’s drug candidate OX219 for treatment of opioid dependence is gathering momentum. A clinical Phase I study was carried out to decide the commercial...

SwedenSweden

20.08.2011

Petach Tikva/Lund – Active Biotech AB suffered a severe setback in the development of its oral multiple sclerosis drug laquinimod. Together with ally Teva (Israel), the Swedish drugmaker announced that the substance failed in...

SwedenSweden

08.08.2011

Lund - Researchers from Lund University may have found a viable alternative to animal testing. In an article in the open access journal BMC Genomics (August 2011) they demonstrated that the response of laboratory grown human...

SwedenSweden

04.08.2011

Uppsala - After good interim results Oasmia wastes no time and starts the approval process for its ovarian cancer drug Paclical. The interim analysis, based on data from approximately 400 patients, showed the expected efficacy of...

SwedenSweden

02.08.2011

Petach Tikva/Lund - Active Biotech's experimental multiple sclerosis drug laquinimod failed in a phase III-trial. This is a major setback for the Swedish drug maker and its ally Teva Pharmaceutical Industries from Israel. Both...

SwedenSweden

30.06.2011

Huddinge, Sweden - Medivir cashes in on Medivir. For EUR 31m the Swedishspecialty pharma company sold all North American remaining rights forXerese, a drug against cold sores (herpes labialis), to Swedish Meda. InFebruary 2010,...

SwedenSweden

15.06.2011

Uppsala/Tokyo – Orexo AB’s cancer pain treatment Abstral has reached the Canadian drug market. The Swedish drugmaker confirmed yesterday that Paladin Labs Inc have launched marketing of the sublingual formulation of fentanyl in...

SwedenSweden

12.06.2011

Stockholm – Swedish investor Karolinska Development AB outperformed its own expectations in its Initial Public Offering on the Nasdaq OMX Stockholm. The company sold 15.2 million shares at SEK40 during the offering, raising a...

Displaying results 11 to 20 out of 182

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-sweden/browse/1/article/biotage-acquires-separtis-holding.html

Image Gallery

Stock list

All quotes

TOP

  • MORPHOSYS (D)62.00 EUR11.8%
  • BIOINVENT INTERNATIONAL AB (S)2.96 SEK10.9%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%

FLOP

  • CYTOS (CH)0.17 CHF-26.1%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)9.94 USD-9.7%

TOP

  • CO.DON (D)3.30 EUR90.8%
  • BIOTECH PHARMACON (N)17.50 NOK63.6%
  • WILEX (D)0.92 EUR55.9%

FLOP

  • CYTOS (CH)0.17 CHF-94.0%
  • BIONOR PHARMA (N)2.11 NOK-48.0%
  • GW PHARMACEUTICALS (UK)219.25 GBP-39.8%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP791.5%
  • PLETHORA (UK)10.62 GBP585.2%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 17.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper